printlogo
ETH Zuerich - Homepage
Biomacromolecules
 
print
  

IMMUNOHYSTOCHEMISTRY

The protocol has been optimised for the detection of the fibronectin isoform containing the Extra Domain B and then extensively used both for the detection of other known antigens and the characterisation of antibodies directed against unknown antigens.
As primary antibody, we use recombinant antibody fragments in the scFv format, isolated from the ETH-2 library.  Both purified scFvs and antibody fragments released in bacteria supernatant can be used as primary reagents.
Since the scFvs from the ETH-2 library have a FLAG sequence at the C-terminus, commercially available anti FLAG M2 antibody is used.
The sequence of reagent application is: primary antibody together with anti-FLAG antibody, biotinylated secondary antibody (Biotinylated goat anti-mouse IgG), preformed avidin-biotin-enzyme complex (ABC), substrate solution.

REAGENTS

BUFFERS

TBS:  
  50mM TRIS
  100 mM NaCl
Sol. A:  
  TBS pH 7.4
  0.05% Tween 20
  3% BSA
Sol. B:  
  Sol. A
  3% BSA
Sol. Fast Red:    
  TRIS-HCl  0.1M pH 8.2 58.8 ml
  N,N-DimethylFormammide 1.2 ml
  Naftolo ASMX Phosphate 12 mg
  Levamisole sol. 60 µl


The solution can be stored at 4°C for 7-14 days. In this solution, Fast Red has to be dissolved only just before its use.

Levamisole sol. (1M sol.):    
  TTRIS-HCl 0.1M pH 8.2 1 ml
  Levamisole powder 240.8 mg
MgCl2 sol. (stock solution 100x):  
  0.2 M MgCl2 in TBS


This solution can be stored at -25°C  for a long time

Fast Red Substrate:  
  Red powder must be added to the Fast red solution just before its use
  Add for example 5 mg FastRed powder to 5 ml Fast Red solution
Filter 0.45 µ
Glycergel:  
  Warm at 50°C
  While mounting your slides, leave it upside-down in warm.

PROTOCOL

Fix the sections in cold aceton (-20°C) 10'
Let the slides dry at RT 30'
Immerse in Sol. A 5'-10'
dry with paper without touching the sections  
Block with FCS/Sol.A (1/5) in a moist chamber 30'
Let the solution fall down into paper  
Add the primary antibodies (es. scFv and M2 Ab) diluted in Sol.B (100 µl/section)
Incubate in a moist chamber
1h
NOTE:
-The final concentration of a scFv should be in the range of 2-30 µg/ml
Make dilution series of the primary antibody to calculate the optimal concentration that you need
-Together with the antibody fragment recognising the antigen of interest, add the anti FLAG antibody M2. The final concentration of the M2 antibody should be in the range of 10-50 µg/ml. Try with a dilution series to find the optimal working concentration for your protocol.
 
   
Rinse twice by directly applying the buffer on the section with a Pasteur pipet, followed by immersion of the slides on buffer twice, 5' each time.  
   
   
Incubate in a moist chamber 30'
Make a dilution series of the antibody in the range of 1/100-1/400 to choose the optimal concentration of the secondary antibody for your protocol.  
Wash by immersion in Sol.A 5'+5'
Dry with paper the back of the slides  
Add the Streptavidin-Biotinylated Alkaline Phosphatase Complex. Dilute the complex in Sol. B and add MgCl2  (final concentration 0.002M). Usually a dilution 1/400 of the complex is necessary.  
Incubate in a moist chamber 30 '
Wash by immersion in Sol.A 5'+5'
Dry with paper the back of the slides  
Add the substrate (dissolve fastRed powder in Sol. Fast Red as already explained in the "buffer" section). Use 500 ul/slide.
 
Incubate in a moist chamber 20 '
Wash with deionised water: twice directly applying the water on the section with a Pasteur pipet and then leave the slides in water.  
Transfer the slides in Gillís Hematoxilin solution n.2 for 50''
Quickly transfer the slides in water and rinse with water for 6 times  
Mount the slides with Glycergel
 

Wichtiger Hinweis:
Diese Website wird in älteren Versionen von Netscape ohne graphische Elemente dargestellt. Die Funktionalität der Website ist aber trotzdem gewährleistet. Wenn Sie diese Website regelmässig benutzen, empfehlen wir Ihnen, auf Ihrem Computer einen aktuellen Browser zu installieren. Weitere Informationen finden Sie auf
folgender Seite.

Important Note:
The content in this site is accessible to any browser or Internet device, however, some graphics will display correctly only in the newer versions of Netscape. To get the most out of our site we suggest you upgrade to a newer browser.
More information

© 2012 ETH Zurich | Imprint | Disclaimer | 13 December 2005
top